Esperoct: payments to doctors
Payments that named Esperoct as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $534K
- Providers
- 273
- Transactions
- 628
- Average per transaction
- $851
The per-transaction average — $851 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 273 providers the average total is $1,957, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Novo Nordisk | $518,576 | 97.1% |
| Novo Nordisk Health Care AG | $15,725 | 2.9% |